Affimed
AFMD
$5.07
Share price
-3.06%
Change (1 day)
533.75%
Change (1 year)
Categories
Earnings for Affimed (AFMD)
Earnings in 2023 (TTM): -$0.12 B
According to Affimed 's latest financial reports the company's current earnings (TTM) are -$0.12 B. In 2022 the company made an earning of -$90.9 M a decrease over its 2021 earnings that were of -$66.65 M.The earnings displayed on this page is the company's Pretax Income.
Earnings history for Affimed from 2013 to 2023
Annual earnings
| Year | Earnings | Change |
|---|---|---|
| 2023 (TTM) | -$0.12 B | 26.4% |
| 2022 | -$90.9 M | 36.4% |
| 2021 | -$66.65 M | 38.24% |
| 2020 | -$48.21 M | 33.41% |
| 2019 | -$36.14 M | 54.5% |
| 2018 | -$23.39 M | -32.55% |
| 2017 | -$34.68 M | -3.29% |
| 2016 | -$35.86 M | 59.37% |
| 2015 | -$22.5 M | 3399.76% |
| 2014 | -$0.65 M | -98.14% |
| 2013 | -$34.65 M |
Earnings for similar companies or competitors
| Company | Earnings | Earnings differencediff. | Country |
|---|---|---|---|
 Repligen
RGEN | $66.08 M | -157.52% | 🇺🇸 USA |
 Merrimack Pharmaceuticals MACK | -$2.18 M | -98.11% | 🇺🇸 USA |
 Agenus
AGEN | -$0.16 B | 38.84% | 🇺🇸 USA |
 Acorda Therapeutics
ACOR | -$0.27 B | 129.65% | 🇺🇸 USA |